Musk emphasizes that he will not promote any cryptocurrency, reminding investors to be wary of deepfake videos
PANews reported on July 29th, according to U.Today, Elon Musk participated in the X Takeover podcast of the Tesla Owners Silicon Valley Club. In this program, Musk acknowledged the advantages of Bitcoin and other cryptocurrencies but emphasized that he does not promote any cryptocurrency. He admitted his preference for Dogecoin due to his love for dogs and memes but insisted that any promotion was just a joke. He also warned that videos showing his support for cryptocurrencies could very likely be deepfake videos. Although Musk has not mentioned Dogecoin on Twitter recently, his companies Tesla and SpaceX still accept Dogecoin as payment for goods, and he plans to continue with the DOGE-1 moon mission.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Terranor Group schedules Q3 results presentation
WTI crude oil futures prices fall by more than 1%

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment
According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.
GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions
Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.